Calcitonin gene-related peptide (CGRP) is a neuropeptide with diverse physiological
functions. Its two isoforms (α and β) are widely expressed throughout the body in sensory …

It has been more than three decades since the first monoclonal antibody was approved by
the United States Food and Drug Administration (US FDA) in 1986, and during this time …

Dysregulation of peptide-activated pathways causes a range of diseases, fostering the
discovery and clinical development of peptide drugs. Many endogenous peptides activate G …

Vasoactive intestinal polypeptide receptor (VIP1R) is a widely expressed class BG protein-
coupled receptor and a drug target for the treatment of neuronal, metabolic, and …

INTRODUCTION Transmembrane signaling of heterotrimeric guanine nucleotide–binding
protein (G protein)–coupled receptors (GPCRs) is mediated by ligand-dependent …

Peptide drugs targeting class B1 G-protein-coupled receptors (GPCRs) can treat multiple
diseases; however, there remains substantial interest in the development of orally delivered …

The parathyroid hormone receptor-1 (PTH1R) is a class BG protein–coupled receptor
central to calcium homeostasis and a therapeutic target for osteoporosis and …

Class B G-protein-coupled receptors are major targets for the treatment of chronic diseases,
including diabetes and obesity. Structures of active receptors reveal peptide agonists …

Class BG protein–coupled receptors, an important class of therapeutic targets, signal mainly
through the Gs class of heterotrimeric G proteins, although they do display some promiscuity …

Targeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however,
many patients with migraine do not benefit from drugs that antagonize the CGRPergic …